Pharmas NDA for APF530 in prevention of CINV: FDA problems Complete Response Letter A.

Source A.P. Pharma.. A.P. Pharma’s NDA for APF530 in prevention of CINV: FDA problems Complete Response Letter A.P. Pharma, Inc. , a specialty pharmaceutical company, announced that it received a Total Response Letter from the today U.S. Meals and Drug Administration regarding its New Drug Software for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting . A meeting call has been scheduled for Friday, March 19, 2010 at 9:00 a.m. Eastern Time. A Complete Response Letter is released by the FDA’s Center for Drug Evaluation and Study when the review of a document is completed and questions stay that preclude the authorization of the NDA in its current form.It also has provided select endowment gifts to support medical and education needs at the local community level. About The Children’s Medical center of Philadelphia Founded in 1855, The Children’s Hospital of Philadelphia is the birthplace of pediatric medication in the us. Throughout its history, a passionate spirit of innovation has driven this famous organization to pursue scientific discovery, establish the best standards of patient care, train potential leaders in pediatrics and advocate for children’s health. A haven of expect families and children worldwide, CHOP is a non-profit charitable organization that relies on the generous support of its donors to continue to set the global standard for pediatric care.